PRX-102 Shown to Safely Improve Kidney Function in Adults With Fabry

PRX-102 Shown to Safely Improve Kidney Function in Adults With Fabry

282610

PRX-102 Shown to Safely Improve Kidney Function in Adults With Fabry

PRX-102 (pegunigalsidase alfa), an experimental enzyme replacement therapy (ERT) for Fabry disease, safely led to significant improvements in kidney function and slowed the progression of kidney disease in men and women previously treated with Replagal (agalsidase alfa). These are the final results from the open-label Phase 3 BRIDGE trial (NCT03018730), which is expected to support a future marketing authorization application for PRX-102 in Europe. “We are excited to have completed the final analysis of our…

You must be logged in to read/download the full post.